GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 1.31x
- P/S forward
- 3.91x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.92x
- Price / sales
- —
- Price / cash flow
- -4.29x
Enterprise value
- Enterprise value
- $30.4M
- EV / sales
- —
- EV / EBITDA
- -1.18x
- EV / EBIT
- -1.18x
- Market cap
- $44.2M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026